Myelodysplastic syndrome after acute promyelocytic leukemia: The European APL group experience

Leukemia

Volumn 17, Issue 8, 2003, Pages 1600-1604

  Lobe, I ^a   Rigal Huguet, F ^b   Vekhoff, A ^c   Desablens, B ^d   Bordessoule, D ^e   Mounier, C ^f   Ferrant, A ^g   Sanz, M ^h   Fey, M ⁱ   Chomienne, C ^j   Chevret, S ^j   Degos, L ^j   Fenaux, Pierre ^k  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c HÔTEL DIEU   (France)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e LIMOGES UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^g Intelartes   (Belgium)

^h HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

ⁱ Insel Hospital   (Switzerland)

^j SAINT LOUIS HOSPITAL   (France)

^k AVICENNE HOSPITAL   (France)

more..

Author keywords

Acute promyelocytic leukemia myelodysplastic syndrome; Therapy related

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BUSULFAN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; RETINOIC ACID; THIOGUANINE DERIVATIVE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER REGRESSION; CANCER RISK; CHROMOSOME 5; CHROMOSOME 7; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DOSE RESPONSE; EUROPEAN UNION; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0041525810     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403034     Document Type: Article

References (29)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451-458.
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. A variant form of hypergranular promyelocytic leukemia (M3). Ann Intern Med 1980; 92: 261.
3. De Botton S, Chevret S, Sanz M, Dombret H, Thomas X, Guerci A. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol. 2000; 111: 801-806.
4. Fenaux P, Chomienne C, Degos L. All-frans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia. Semin Hematol 2001; 38: 13-25.
5. Sanz MA, Martin G, Rayon C, Esteve J, Gonzalez M, Diaz-Mediavilla J et al. A modified AIDA protocol with anthracyclinebased consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999; 94: 3015-3021.
6. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002; 100: 4298-4302.
7. Latagliata R, Petti MC, Fenu S, Mancini M, Spiriti MA, Breccia M et al. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukaemia: an emerging problem. Blood 2002; 99: 822-824.
8. Stasi R, Taylor CG, Venditti A, Del Poeta G, Aronica G, Bastianelli C et al. Contribution of immunophenotypic and genotypic analyses to the diagnosis of acute leukemia. Ann Hematol 1995; 71: 13-27.
9. Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993; 82: 3241-3249.
10. Fenaux P, Chastang C, Chomienne C, Castaigne S, Sanz M, Link H et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: the European experience. European APL Group. Leuk Lymphoma 1995; 16: 431-437.
11. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999; 94: 1192-1200.
12. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
13. Zompi S, Legrand O, Bouscary D, Blanc CM, Picard F, Casadevall N et al. Therapy-related acute myeloid leukaemia after successful therapy for acute promyelocytic leukaemia with t(15;17): a report of two cases and a review of the literature. Br J Haematol 2000; 110: 610-613.
14. Zompi S, Viguie F. Therapy-related acute myeloid leukemia and myelodysplasia after successful treatment of acute promyelocytic leukemia. Leuk Lymphoma 2002; 43: 275-280.
15. Jubashi T, Nagai K, Miyazaki Y, Nakamura H, Matsuo T, Kuriyama K et al. A unique case of t(15;17) acute promyelocytic leukaemia (M3) developing into acute myeloblastic leukaemia (M1) with t(7;21) at relapse. Br J Haematol 1993; 83: 665-668.
16. Miyazaki H, Ino T, Sobue R, Kojima H, Wakita M, Nomura T et al. Translocation (3;21)(q26;q22) in treatment-related acute leukemia secondary to acute promyelocytic leukemia. Cancer Genet Cytogenet 1994; 74: 84-86.
17. Hatzis T, Standen GR, Howell RT, Savill C, Wagstaff M, Scott GL. Acute promyelocytic leukaemia (M3): relapse with acute myeloblastic leukaemia (M2) and dic(5;17) (q11;p11). Am J Hematol 1995; 48:40-44.
18. Todisco E, Testi AM, Avvisati G, Moleti ML, Cedrone M, Cimino G et al. Therapy-related acute myelomonocytic leukemia following successful treatment for acute promyelocytic leukemia. Leukemia 1995; 9: 1583-1585.
19. Bseiso AW, Kantarjian H, Estey E. Myelodysplastic syndrome following successful therapy of acute promyelocytic leukemia. Leukemia 1997; 11: 168-169.
20. Meloni G, Diverio D, Vignetti M, Avvisati G, Capria S, Petti MC et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood 1997; 90: 1321-1325.
21. Sawada H, Morimoto H, Wake A, Yamasaki Y, Izumi Y. Therapy-related acute myeloid leukemia with t(10;11)(q23;p15) following successful chemotherapy for acute promyelocytic leukemia with t(15;17)(q22;q21). Int J Hematol 1999; 69: 270-271.
22. Stavroyianni N, Yataganas X, Abazis D, Pangalos C, Meletis J. Acute promyelocytic leukemia relapsing into FAB-M2 acute myeloid leukemia with trisomy 8. Cancer Genet Cytogenet 2000; 117: 82-83.
23. Au WY, Lam CC, Ma ES, Man C, Wan T, Kwong YL. Therapy-related myelodysplastic syndrome after eradication of acute promyelocytic leukemia: cytogenetic and molecular features. Hum Pathol 2001; 32: 126-129.
24. Felice MS, Rossi J, Gallego M, Zubizarreta PA, Cygler AM, Alfaro E et al. Acute trilineage leukemia with monosomy of chromosome 7 following an acute promyelocytic leukemia. Leuk Lymphoma 1999; 34: 409-413.
25. Pecci A, Invernizzi R. A therapy-related myelodysplastic syndrome with unusual features in a patient treated for acute promyelocytic leukemia. Haematologica 2001; 86: 102-103.
26. Pedersen-Bjergaard J, Philip P, Larsen SO, Jensen G, Byrsting K. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukaemia. Blood 1990; 76: 1083-1091.
27. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995; 86: 3542-3552.
28. Lo Coco F, Latagliata R, Diverio D, Breccia M, Chiusolo P, Mandelli F. Independent clonal origin of therapy-related MDS-AML developing after treatment of acute promyelocytic leukemia. Blood 2002; 100: 1929.
29. Klarskov Andersen M, Pedersen-Bjergaard J. Therapy-related MDS and AML in acute promyelocytic leukemia. Blood 2002; 100: 1928-1929.